⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-06
· read from full text
ⓘ
This study evaluated the utility of serum CA19-9 and CA125 levels for preoperative diagnosis in 195 patients with ovarian endometriosis or epithelial ovarian tumors compared to 113 healthy controls. The researchers found that these biomarkers effectively differentiated ovarian endometriosis from serous adenocarcinoma, although they could not distinguish it from other epithelial ovarian tumor subtypes. Additionally, elevated CA19-9 levels were associated with stage I mucinous borderline tumors featuring interstitial infiltration, suggesting its potential as a marker for inflammatory carcinogenesis and drug susceptibility. This paper is centrally about ovarian endometriosis, specifically examining its histological relationship with various epithelial ovarian tumors through serum biomarker analysis.
Abstract
Previous reports have shown that some ovarian endometrioid adenocarcinomas and ovarian clear cell adenocarcinomas derive from ovarian endometriosis (OE), and that endocervical-like mucinous borderline ovarian tumors are associated with OE. We examined the relationship between the staging and histological subtypes of OE or epithelial ovarian tumors (EOT) and the serum levels of carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) to evaluate the potential of these markers for preoperative diagnosis. First, we analyzed the preoperative serum levels of CA19-9 and CA125 in 195 patients who were histopathologically diagnosed with OE or EOT. We then performed a case-control study in which 308 women were enrolled, the 195 women described above and 113 healthy women as control subjects. Serum CA19-9 and CA125 levels were found to be useful in differentiating between OE and serous adenocarcinoma, but not between OE and other EOT. Moreover, serum CA19-9 levels were useful for preoperative assessment between OE and stage I mucinous borderline ovarian tumors, with or without the interstitial infiltration. In addition, considering that the serum CA19-9 levels in stage I mucinous borderline ovarian tumors were elevated via the interstitial infiltration of leukocytes and that precancerous lesions are associated with a cancerous glycosylation disorder in the process of inflammatory carcinogenesis, the CA19-9 level may be considered a suitable biomarker for estimating drug susceptibility.
Full text
2,368 characters
· extracted from
oa-doi-fallback
· click to expand
| ID | 53559 |
| JaLCDOI | |
| FullText URL | |
| Author |
Nakagawa, Naohisa
Koda, Hiromi
Nitta, Noriko
Nakahara, Yukie
Uno, Jiro
Hashimoto, Toru
Nakahori, Takashi
Hasegawa, Masaaki
Kataoka, Mikio
|
| Abstract | Previous reports have shown that some ovarian endometrioid adenocarcinomas and ovarian clear cell adenocarcinomas derive from ovarian endometriosis (OE), and that endocervical-like mucinous borderline ovarian tumors are associated with OE. We examined the relationship between the staging and histological subtypes of OE or epithelial ovarian tumors (EOT) and the serum levels of carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) to evaluate the potential of these markers for preoperative diagnosis. First, we analyzed the preoperative serum levels of CA19-9 and CA125 in 195 patients who were histopathologically diagnosed with OE or EOT. We then performed a case-control study in which 308 women were enrolled, the 195 women described above and 113 healthy women as control subjects. Serum CA19-9 and CA125 levels were found to be useful in differentiating between OE and serous adenocarcinoma, but not between OE and other EOT. Moreover, serum CA19-9 levels were useful for preoperative assessment between OE and stage I mucinous borderline ovarian tumors, with or without the interstitial infiltration. In addition, considering that the serum CA19-9 levels in stage I mucinous borderline ovarian tumors were elevated via the interstitial infiltration of leukocytes and that precancerous lesions are associated with a cancerous glycosylation disorder in the process of inflammatory carcinogenesis, the CA19-9 level may be considered a suitable biomarker for estimating drug susceptibility.
|
| Keywords | ovarian endometriosis
epithelial ovarian tumors
histological subtype
carbohydrate antigen 19-9
carbohydrate antigen 125
|
| Amo Type | Original Article
|
| Publication Title |
Acta Medica Okayama
|
| Published Date | 2015-08
|
| Volume | volume69
|
| Issue | issue4
|
| Publisher | Okayama University Medical School
|
| Start Page | 227
|
| End Page | 235
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| Content Type |
Journal Article
|
| language |
English
|
| Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School
|
| File Version | publisher
|
| Refereed |
True
|
| PubMed ID | |
| Web of Science KeyUT |
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.
MeSH descriptors
CA-125 Antigen
CA-19-9 Antigen
Endometriosis
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Biomarkers, Tumor
CA-125 Antigen
CA-19-9 Antigen
Carcinoma, Ovarian Epithelial
Case-Control Studies
Endometriosis
Endometriosis
Female
Humans
Middle Aged
Neoplasms, Glandular and Epithelial